Division of Nephrology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.
Division of Nephrology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
PLoS One. 2020 Jan 21;15(1):e0227694. doi: 10.1371/journal.pone.0227694. eCollection 2020.
Diabetes is a global epidemic, and the high cost of annually and quantitatively measuring urine albumin excretion using the turbidimetric immunoassay is challenging. We aimed to determine whether a semi-quantitative urinary albumin-creatinine ratio test could be used as a screening tool for microalbuminuria in diabetic patients.
We assessed the diagnostic accuracy of the semi-quantitative method. The costs of false results in the semi-quantitative method were calculated based on the annual probability of disease progression analyzed through a systematic literature review and meta-analysis. The pooled long-term cost-saving effect of the semi-quantitative method compared with the quantitative test was assessed using a Markov model simulating a long-term clinical setting. Diagnostic accuracy and the cost-saving effect were also validated in an independent external cohort.
Compared with the quantitative test, the semi-quantitative method had sensitivities of 93.5% and 81.3% and specificities of 61.4% and 63.1% in the overall sample of diabetic patients (n = 1,881) and in diabetic patients with eGFR ≥60 ml/min/1.73 m2 and a negative dipstick test (n = 1,110), respectively. After adjusting for direct and indirect medical costs, including the risk of disease progression, which was adjusted by the meta-analyzed hazard ratio for clinical outcomes, it was determined that using the semi-quantitative method could save 439.4 USD per person for 10 years. Even after adjusting the result to the external validation cohort, 339.6 USD could be saved for one diabetic patient for 10 years.
The semi-quantitative method could be an appropriate screening tool for albuminuria in diabetic patients. Moreover, it can minimize the testing time and inconvenience and significantly reduce national health costs.
糖尿病是一种全球性的流行病,使用比浊免疫分析法每年定量检测尿白蛋白排泄量的成本很高。本研究旨在确定半定量尿白蛋白-肌酐比值检测是否可作为糖尿病患者微量白蛋白尿的筛查工具。
我们评估了半定量方法的诊断准确性。根据系统文献回顾和荟萃分析分析的疾病进展年概率,计算了半定量方法中假阳性结果的成本。使用模拟长期临床环境的马尔可夫模型评估了半定量方法与定量检测相比的长期节省成本效果。还在独立的外部队列中验证了诊断准确性和节省成本的效果。
与定量检测相比,半定量方法在糖尿病患者(n=1881)和 eGFR≥60 ml/min/1.73 m2且尿试纸检测阴性的糖尿病患者(n=1110)的总体样本中具有 93.5%和 81.3%的敏感性和 61.4%和 63.1%的特异性。在调整了直接和间接医疗成本(包括通过荟萃分析的临床结局风险比调整疾病进展风险)后,确定使用半定量方法可在 10 年内为每人节省 439.4 美元。即使将结果调整到外部验证队列,每位糖尿病患者在 10 年内也可节省 339.6 美元。
半定量方法可能是糖尿病患者白蛋白尿的一种合适的筛查工具。此外,它可以最大限度地减少检测时间和不便,显著降低国家卫生保健成本。